Copeptin in Differentiation of Polyuria and Polydipsia

This study has been completed.

Sponsor:

Collaborator:

Dr. Carson Liu Med Corp.

Information provided by:

University of Wuerzburg

ClinicalTrials.gov Identifier:

NCT01056887

First received: January 25, 2010

Last updated: April 22, 2011

Last verified: November 2010

History of Changes

Purpose

The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy.

Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities.

The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably.

C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure.

Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.

Condition
Polyuria Polydipsia

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective

Resource links provided by NLM:

Genetics Home Reference related topics: neurohypophyseal diabetes insipidus

MedlinePlus related topics: Diabetes Insipidus

U.S. FDA Resources

Further study details as provided by University of Wuerzburg:

Estimated Enrollment:	50
Study Start Date:	March 2008
Study Completion Date:	November 2010
Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts
Primary Polydip, D. insipidus

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Healthy probands Patients with diabetes insipdus centralis totalis/ partials Patients with diabetes insipidus renalis Patients with primary polydipsia

Criteria

Inclusion Criteria:

Patients with polydipsia/ polyuria, with indication for performing a deprivation test
> 18 years

Exclusion Criteria:

dDAVP during the last 14d
pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01056887

Locations

Germany
Univ Hospital Wuerzburg
Wuerzburg, Bavaria, Germany, 97080

Sponsors and Collaborators

University of Wuerzburg

Dr. Carson Liu Med Corp.

More Information

No publications provided by University of Wuerzburg

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, Pfeiffer AF, Fassnacht M, Störk S, Allolio B. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011 May;96(5):1506-15. Epub 2011 Mar 2.

Responsible Party:	Prof. Dr. med. Bruno Allolio, FDAAA
ClinicalTrials.gov Identifier:	NCT01056887 History of Changes
Other Study ID Numbers:	17121979, 33/07
Study First Received:	January 25, 2010
Last Updated:	April 22, 2011
Health Authority:	Germany: The Bavarian State Ministry of the Environment and Public Health

Keywords provided by University of Wuerzburg:

diabetes insipidus
primary polydipsia
copeptin
Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test

Additional relevant MeSH terms:

Polyuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on May 21, 2013

To Top